9011-93-2

Lysostaphin (5 mg/kg, intravenous injection, once daily for 3 consecutive days) effectively clears systemic Staphylococcus aureus (MSSA) infections in CF-1 mice^[2]. Lysostaphin (50 mg/kg, intravenous injection, single dose) effectively clears Staphylococcus aureus (MSSA and MRSA) infections from the kidneys, spleen, and liver, but is not superior to repeated lower doses^[2]. Lysostaphin (1 mg/kg, intravenous injection, once daily for 3 consecutive days) combined with Oxacillin (HY-B0925A) achieves the same antibacterial effect with a lower concentration of Lysostaphin. When combined with Vancomycin, low-dose Lysostaphin (1 mg/kg) similarly shows enhanced efficacy against MRSA^[2].